AU2002363228A1 - Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750 - Google Patents

Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750

Info

Publication number
AU2002363228A1
AU2002363228A1 AU2002363228A AU2002363228A AU2002363228A1 AU 2002363228 A1 AU2002363228 A1 AU 2002363228A1 AU 2002363228 A AU2002363228 A AU 2002363228A AU 2002363228 A AU2002363228 A AU 2002363228A AU 2002363228 A1 AU2002363228 A1 AU 2002363228A1
Authority
AU
Australia
Prior art keywords
diagnosis
compositions
treatment
methods
cellular proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002363228A
Other languages
English (en)
Inventor
Mark Williamson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of AU2002363228A1 publication Critical patent/AU2002363228A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002363228A 2001-10-31 2002-10-29 Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750 Abandoned AU2002363228A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33500601P 2001-10-31 2001-10-31
US60/335,006 2001-10-31
PCT/US2002/034574 WO2003037257A2 (en) 2001-10-31 2002-10-29 Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750

Publications (1)

Publication Number Publication Date
AU2002363228A1 true AU2002363228A1 (en) 2003-05-12

Family

ID=23309830

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002363228A Abandoned AU2002363228A1 (en) 2001-10-31 2002-10-29 Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750

Country Status (5)

Country Link
US (1) US20030108937A1 (enExample)
EP (1) EP1440080A4 (enExample)
JP (1) JP2005508169A (enExample)
AU (1) AU2002363228A1 (enExample)
WO (1) WO2003037257A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508169A (ja) * 2001-10-31 2005-03-31 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ２０７５０を使用した細胞増殖障害の診断および処置のための方法および組成物
WO2003051905A2 (en) * 2001-12-13 2003-06-26 Exelixis, Inc. Taojiks as modifiers of the beta-catenin pathway and methods of use
WO2003074725A2 (en) * 2002-03-01 2003-09-12 Exelixis, Inc. MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
US20070128666A1 (en) * 2003-11-24 2007-06-07 Helen Francis-Lang Ttbks as modifiers of the beta catenin pathway and methods of use
AU2004292672A1 (en) * 2003-11-24 2005-06-09 Exelixis, Inc. TTBKs as modifiers of the beta catenin pathway and methods of use
WO2008150845A1 (en) * 2007-05-31 2008-12-11 Vanderbilt University Screening for wnt pathway modulators and pyrvinium for the treatment of cance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003501038A (ja) * 1999-05-28 2003-01-14 スージェン・インコーポレーテッド 蛋白質キナーゼ
US20020151020A1 (en) * 2001-04-16 2002-10-17 Xianghe Yan Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
JP2005508169A (ja) * 2001-10-31 2005-03-31 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ２０７５０を使用した細胞増殖障害の診断および処置のための方法および組成物

Also Published As

Publication number Publication date
JP2005508169A (ja) 2005-03-31
WO2003037257A3 (en) 2004-01-22
EP1440080A4 (en) 2007-12-12
US20030108937A1 (en) 2003-06-12
WO2003037257A2 (en) 2003-05-08
EP1440080A2 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
WO2003034984A9 (en) Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
WO2002086502A8 (en) Methods for the diagnosis and treatment of bone disorders
AU7722600A (en) Compositions and methods for the diagnosis and treatment of immune disorders
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003213787A1 (en) Compositions and methods for the treatment of anorectal disorders
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
PL366636A1 (en) Pyranoindazoles and their use for the treatment of glaucoma
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU5309600A (en) Compositions and methods for the treatment and diagnosis of immune disorders
AUPS017702A0 (en) Methods and compositions for the treatment of asthma and related disorders
WO2003039490A9 (en) Compositions and methods for diagnosing and treating mental disorders
AU2002362115A1 (en) Composition and methods for treatment of neurological disorders
PL368035A1 (en) Compositions and methods for the treatment of cancer
AU2002346882A1 (en) Methods for the treatment of osteoarthritis and compositions thereof
AU2002249983A1 (en) Compositions and methods for diagnosis of neuropsychiatric disorders
AU2002363228A1 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 20750
AU2002350053A1 (en) Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943
WO2004096848A8 (en) Novel composition and methods for the treatment of immune disorders
AU2002348330A1 (en) Methods and compositions for the diagnosis and treatment of cellular proliferation disorders using 86604
AU2002350055A1 (en) Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 54394
AU2002348324A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 46566
AU2002359331A1 (en) Methods and compositions for the treatment and diagnosis of cellular proliferative disorders using 32222
AU2002360318A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 9805
AU2002359316A1 (en) Methods and compositions for the diagnosis and treatment of hematological disorders using 16319

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase